BACKGROUND: Integrins mediate invasion and angiogenesis in prostate cancer bone metastases. We conducted a phase II study of cilengitide, a selective antagonist of α(v)β(3) and α(v)β(5) integrins, in non-metastatic castration resistant prostate cancer with rising PSA. METHODS: Patients were observed for 4 weeks with PSA monitoring, and then treated with 2,000 mg IV of cilengitide twice weekly until toxicity/progression. PSA, circulating tumor cells (CTCs) and circulating endothelial cells (CECs) were monitored each cycle with imaging performed every three cycles. Primary end point was PSA decline by ≥ 50%. Secondary endpoints were safety, PSA slope, time to progression (TTP), overall survival (OS), CTCs, CECs and gene expression. RESULTS: 16 pts were enrolled; 13 were eligible with median age 65.5 years, baseline PSA 8.4 ng/mL and median Gleason sum 7. Median of three cycles was administered. Treatment was well tolerated with two grade three toxicities and no grade four toxicities. There were no PSA responses; 11 patients progressed by PSA after three cycles. Median TTP was 1.8 months and median OS has not been reached. Median pre- and on-treatment PSA slopes were 1.1 and 1.8 ng/mL/month. Baseline CTCs were detected in 1/9 patients. CTC increased (0 to 1; 2 pts), remained at 0 (2 pts) or decreased (23 to 0; 1 patient) at progression. Baseline median CEC was 26 (0-61) and at progression, 47 (15-148). Low cell counts precluded gene expression studies. CONCLUSIONS: Cilengitide was well tolerated but had no detectable clinical activity. CTCs are of questionable utility in non-metastatic prostate cancer.
BACKGROUND: Integrins mediate invasion and angiogenesis in prostate cancer bone metastases. We conducted a phase II study of cilengitide, a selective antagonist of α(v)β(3) and α(v)β(5) integrins, in non-metastatic castration resistant prostate cancer with rising PSA. METHODS:Patients were observed for 4 weeks with PSA monitoring, and then treated with 2,000 mg IV of cilengitide twice weekly until toxicity/progression. PSA, circulating tumor cells (CTCs) and circulating endothelial cells (CECs) were monitored each cycle with imaging performed every three cycles. Primary end point was PSA decline by ≥ 50%. Secondary endpoints were safety, PSA slope, time to progression (TTP), overall survival (OS), CTCs, CECs and gene expression. RESULTS: 16 pts were enrolled; 13 were eligible with median age 65.5 years, baseline PSA 8.4 ng/mL and median Gleason sum 7. Median of three cycles was administered. Treatment was well tolerated with two grade three toxicities and no grade four toxicities. There were no PSA responses; 11 patients progressed by PSA after three cycles. Median TTP was 1.8 months and median OS has not been reached. Median pre- and on-treatment PSA slopes were 1.1 and 1.8 ng/mL/month. Baseline CTCs were detected in 1/9 patients. CTC increased (0 to 1; 2 pts), remained at 0 (2 pts) or decreased (23 to 0; 1 patient) at progression. Baseline median CEC was 26 (0-61) and at progression, 47 (15-148). Low cell counts precluded gene expression studies. CONCLUSIONS: Cilengitide was well tolerated but had no detectable clinical activity. CTCs are of questionable utility in non-metastatic prostate cancer.
Authors: Riccardo E Nisato; Jean-Christophe Tille; Alfred Jonczyk; Simon L Goodman; Michael S Pepper Journal: Angiogenesis Date: 2003 Impact factor: 9.596
Authors: G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: F P Ross; J Chappel; J I Alvarez; D Sander; W T Butler; M C Farach-Carson; K A Mintz; P G Robey; S L Teitelbaum; D A Cheresh Journal: J Biol Chem Date: 1993-05-05 Impact factor: 5.157
Authors: G Heiduschka; C Lill; S Schneider; R Seemann; G Kornek; R Schmid; U Kotowski; D Thurnher Journal: Strahlenther Onkol Date: 2014-02-21 Impact factor: 3.621
Authors: Tao Wang; Jiayi Huang; Mai Vue; Michael R Alavian; Hira Lal Goel; Dario C Altieri; Lucia R Languino; Thomas J FitzGerald Journal: Mol Cancer Res Date: 2018-09-28 Impact factor: 5.852
Authors: Michael H Ross; Alison K Esser; Gregory C Fox; Anne H Schmieder; Xiaoxia Yang; Grace Hu; Dipanjan Pan; Xinming Su; Yalin Xu; Deborah V Novack; Thomas Walsh; Graham A Colditz; Gabriel H Lukaszewicz; Elizabeth Cordell; Joshua Novack; James A J Fitzpatrick; David L Waning; Khalid S Mohammad; Theresa A Guise; Gregory M Lanza; Katherine N Weilbaecher Journal: Cancer Res Date: 2017-08-30 Impact factor: 12.701
Authors: Afshin Varzavand; Will Hacker; Deqin Ma; Katherine Gibson-Corley; Maria Hawayek; Omar J Tayh; James A Brown; Michael D Henry; Christopher S Stipp Journal: Cancer Res Date: 2016-09-28 Impact factor: 12.701
Authors: Xinming Su; Alison K Esser; Sarah R Amend; Jingyu Xiang; Yalin Xu; Michael H Ross; Gregory C Fox; Takayuki Kobayashi; Veronica Steri; Kirsten Roomp; Francesca Fontana; Michelle A Hurchla; Brett L Knolhoff; Melissa A Meyer; Elizabeth A Morgan; Julia C Tomasson; Joshua S Novack; Wei Zou; Roberta Faccio; Deborah V Novack; Stephen D Robinson; Steven L Teitelbaum; David G DeNardo; Jochen G Schneider; Katherine N Weilbaecher Journal: Cancer Res Date: 2016-05-23 Impact factor: 12.701